Blueprint Medicines (BPMC) PT Raised to $55 at Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq set for higher open as oil prices extend declines, midterm results awaited
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Price: $129.46 --0%
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Join SI Premium – FREE
Wells Fargo analyst Derek Archila raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $55.00 (from $48.00) while maintaining a Equal Weight rating.
You May Also Be Interested In
- Essential Properties Realty Trust (EPRT) PT Lowered to $31 at Cantor Fitzgerald
- MYR Group (MYRG) PT Lowered to $386 at Stifel
- Napco Security Technologies, Inc. (NSSC) PT Lowered to $45 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
